Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukemogenesis by CBF oncoproteins.

A D Friedman1

  • 1Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Leukemia
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The C-terminal multimerization domain is essential for leukemia development by CBFβ-SMMHC in a mouse knockin model.

Leukemia·2017
Same author

The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.

Leukemia·2017
Same author

CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.

Oncogene·2015
Same author

Submucosal neoplasms of the laryngeal introitus.

The Journal of laryngology and otology·2012
Same author

Value and utility of 532 nanometre pulsed potassium-titanyl-phosphate laser in endoscopic laryngeal surgery.

The Journal of laryngology and otology·2009
Same author

C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters.

Leukemia·2008
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
Same journal

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same journal

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.

Leukemia·2026
See all related articles

Core binding factor (CBF) oncoproteins, like AML1-ETO, are implicated in acute leukemias. These fusion proteins may drive cancer by disrupting normal CBF function, potentially inhibiting cell differentiation and survival.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Core binding factor (CBF) is crucial for normal hematopoiesis.
  • Chromosomal abnormalities involving AML1 and CBFbeta subunits are common in acute leukemias.
  • Several fusion proteins, including AML1-ETO and TEL-AML1, arise from these abnormalities.

Purpose of the Study:

  • To investigate the role of CBF-related fusion proteins in leukemogenesis.
  • To understand how these oncoproteins contribute to the development of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).

Main Methods:

  • Analysis of gene expression in leukemia subsets.
  • Investigating the mechanism of action of CBF fusion proteins.

Main Results:

Related Experiment Videos

  • CBFbeta-SMMHC, AML1-ETO, and AML1-MDS1/EVI1 fusion proteins are expressed in AML.
  • TEL-AML1 fusion protein is expressed in B-lineage ALL.
  • These oncoproteins are hypothesized to inhibit endogenous CBF activity.

Conclusions:

  • CBF fusion proteins are key players in acute leukemia pathogenesis.
  • Inhibition of normal CBF function by these oncoproteins likely impairs cell differentiation and apoptosis.
  • Unique domains within fusion proteins may confer specific oncogenic mechanisms.